Eric Dobmeier News Today

ProfoundBio has secured $112m in a Series B financing round to advance its clinical-stage antibody-drug conjugate (ADC) pipeline for cancer treatment.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

SEATTLE, July 28, 2023 -- Chinook Therapeutics, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today...

Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Free Report) have been assigned a consensus recommendation of “Hold” from the thirteen research firms that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average […]

Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Free Report) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 3,130,000 shares, an increase of 72.0% from the June 15th total of 1,820,000 shares. Based on an average daily volume of 1,410,000 shares, […]

Chinook Therapeutics, Inc. (NASDAQ:KDNY – Free Report) was the target of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 1,820,000 shares, a decline of 56.4% from the May 31st total of 4,170,000 shares. Based on an average daily volume of 1,330,000 shares, the […]

William Blair cut shares of Chinook Therapeutics (NASDAQ:KDNY – Get Rating) from an outperform rating to a market perform rating in a report published on Monday morning, The Fly reports. A number of other research analysts also recently issued reports on KDNY. HC Wainwright lifted their price objective on shares of Chinook Therapeutics from $31.00 […]

Guggenheim lowered shares of Chinook Therapeutics (NASDAQ:KDNY – Get Rating) from a buy rating to a neutral rating in a report published on Monday morning, The Fly reports. A number of other equities research analysts have also recently commented on KDNY. Piper Sandler started coverage on shares of Chinook Therapeutics in a research note on […]

Stifel Nicolaus cut shares of Chinook Therapeutics (NASDAQ:KDNY – Get Rating) from a buy rating to a hold rating in a research note published on Tuesday, The Fly reports. Several other research firms have also commented on KDNY. SVB Securities lowered shares of Chinook Therapeutics from an outperform rating to a market perform rating in […]

Chinook Therapeutics (NASDAQ:KDNY – Get Rating) was downgraded by investment analysts at SVB Leerink from an “outperform” rating to a “market perform” rating in a research note issued on Tuesday, PriceTargets.com reports. Several other brokerages have also recently commented on KDNY. William Blair cut Chinook Therapeutics from an “outperform” rating to a “market perform” rating […]